Innate Pharma SA is a global, clinical-stage biotechnology company, which engages in developing immunotherapies for cancer patients. Its product pipeline includes Lacutamab, Monalizumab, Avdoralimab, and IPH62. The company was founded by Hervé Eloi Dominique Brailly, Eric Vivier, Marc Bonneville, Alessandro Moretta, Jean-Jacques Fournié, and Fran?ois Romagné on September 23, 1999 and is headquartered in Marseille, France.
相关临床试验
10
10 进行中
药物批准
0
批准总数
监管机构
0
监管机构数
成立时间
1999
进行中（未招募）
10
100.0%
暂无批准数据
- Sobi and Innate Pharma announced a strategic partnership to enable the TELLOMAK-3 confirmatory Phase 3 study of lacutamab in cutaneous T-cell lymphoma. - Sobi receives exclusive global commercialization rights to lacutamab upon potential accelerated approval and may assume full global development rights following positive Phase 3 results. - Innate will receive USD 75 million upfront, up to USD 40 million in near-term milestones, and up to USD 465 million in additional regulatory and commercial milestones, plus tiered double-digit royalties. - Lacutamab, a first-in-class anti-KIR3DL2 antibody, has received FDA Breakthrough Therapy, Fast Track, and Orphan Drug designations, as well as EMA PRIME designation for Sézary syndrome.
- Innate Pharma completed enrollment of 76 patients in the dose escalation portion of the Phase 1 IPH4502-101 study across sites in France and the United States. - IPH4502, a Nectin-4-targeting ADC with an exatecan payload and proprietary linker, has shown a favorable safety profile with limited hematological toxicity to date. - Objective responses were observed in heavily pre-treated patients with post-enfortumab vedotin urothelial carcinoma, non-small cell lung cancer, and head and neck squamous cell carcinoma. - Preliminary data from the dose escalation are expected by year-end and will guide dose optimization in selected tumor types.
- Prescient Therapeutics' PTX-100 is the world's first and only GGTase-1 inhibitor in clinical trials, targeting relapsed/refractory cutaneous T-cell lymphoma (r/r CTCL). - Phase 1b data showed a 100% clinical benefit rate in the CTCL subgroup, a 45% overall response rate, and a 64% clinical benefit rate with serious adverse events at only 4%. - The global Phase 2a trial has accelerated to 28 enrolled patients across Australia, the US, and Europe, with a Dose Optimisation Committee meeting expected during 2026. - Prescient is exploring whether Phase 2b could serve as a registrational study, supported by FDA Orphan Drug and Fast Track designations and EMA Orphan Drug Designation.
- Innate Pharma plans to initiate the confirmatory Phase 3 TELLOMAK-3 trial for lacutamab in cutaneous T-cell lymphoma in H2 2026, following FDA clearance and Breakthrough Therapy Designation for Sézary syndrome. - IPH4502, the company's Nectin-4 antibody-drug conjugate, demonstrates preliminary anti-tumor activity with favorable safety profile in heavily pre-treated patients with advanced solid tumors. - The company faces financial challenges with €44.8 million cash position providing runway only until Q3 2026, prompting negotiations for non-dilutive financing options including pharma partnerships. - Multiple Phase 3 trials are advancing, including PACIFIC-9 with AstraZeneca for monalizumab in non-small cell lung cancer, with data readout expected in H2 2026.
- Curogen, a South Korean biotechnology company focused on nanotechnology-based autoimmune treatments, has appointed Arvind Sood as Global Chief Operating Officer to establish and grow its US operations. - The company expanded its board of directors with seven distinguished leaders, including rheumatology expert Dr. Allan Gibofsky and biotech investor Dr. Craig Gordon, to support its global expansion strategy. - Curogen's preclinical pipeline includes innovative small molecules and multi-specific TRAP proteins targeting inflammatory bowel disease, hidradenitis suppurativa, and other high unmet need autoimmune conditions. - The strategic appointments position Curogen to accelerate research and development efforts while expanding its footprint in US and global markets with novel oral drug approaches for autoimmune diseases.
- Innate Pharma's IPH6501, a tetra-specific NK cell engager, targets CD20 and activates NK cells via NKp46, CD16, and an IL-2 variant receptor, showing potential in B-NHL. - Preclinical studies of IPH6501 demonstrated higher efficacy and lower toxicity compared to T cell engagers in mouse models and non-human primates. - IPH6501 induced NK cell proliferation and migration to tumor sites, exhibiting anti-tumor activity even against CD20-negative cells and in rituximab-resistant models. - Currently, IPH6501 is undergoing Phase I/II dose-escalation trials in relapsed or unresponsive B-NHL patients, with initial study designs presented at ASCO 2024.
